Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Ocumension Therapeutics 14-Day RSI Related Terms
FRA:5DG vs VRTX, REGN, RVMD: 14-Day RSI Comparison
For the Biotechnology subindustry, Ocumension Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocumension Therapeutics 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Ocumension Therapeutics's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocumension Therapeutics (FRA:5DG) has a 14-Day RSI of 49.27 as of Aug. 05, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Ocumension Therapeutics and its competitors. According to the industry distribution chart, Ocumension Therapeutics ranks #697 out of 1422 companies in the Biotechnology industry, placing it in the top 49%.
Is Ocumension Therapeutics' 14-Day RSI too high?
Ocumension Therapeutics' current 14-Day RSI is 49.27. The Biotechnology industry median 14-Day RSI is 48.00. Ocumension Therapeutics' value of 49.27 is 2.6% above this industry median. Based on the distribution chart, Ocumension Therapeutics ranks #697 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ocumension Therapeutics has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ocumension Therapeutics' 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ocumension Therapeutics ranks #697 out of 1422 companies for 14-Day RSI. This puts Ocumension Therapeutics in the upper half of its industry. The industry median 14-Day RSI is 48.00. Ocumension Therapeutics' value of 49.27 is 2.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 48.00, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ocumension Therapeutics's current 14-Day RSI of 49.27 is 2.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Ocumension Therapeutics and its competitors. For the Biotechnology industry, the median 14-Day RSI is 48.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ocumension Therapeutics's current 14-Day RSI is 49.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocumension Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ocumension Therapeutics (FRA:5DG) is currently considered Possible Value Trap. The stock's GF Value™ is €2.08, compared to a current price of €0.54 — trading 74% below its estimated fair value. The current 14-Day RSI is 49.27 and 2.6% above the Biotechnology industry median of 48.00. Ocumension Therapeutics' overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Ocumension Therapeutics (FRA:5DG), the current 14-Day RSI is 49.27 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ocumension Therapeutics (FRA:5DG) Overvalued in 2026?
Based on GuruFocus' analysis, Ocumension Therapeutics stock appears to be undervalued.
The current stock price of €0.54 is trading 74% below its estimated GF Value™ of €2.08.
GuruFocus considers Ocumension Therapeutics to be Possible Value Trap.
Key valuation signals for FRA:5DG:
14-Day RSI: 49.27
GF Value™: €2.08 vs. price of €0.54 (74% below fair value)
Industry Position: 2.6% above the Biotechnology median (#697 of 1422)
No single metric tells the full story. See the FRA:5DG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
65GF Score
Get the complete analysis for FRA:5DG
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5DG has been successfully added to your 
